Aducanumab: A Deep Dive into BIIB037 and its Impact A drug, previously known as BIIB037, constitutes a complex endeavor to address early-stage Alzheimer's condition. Developed by Biogen, aducanumab functions by https://www.targetmol.com/compound/aducanumab